Tylenol Autism & ADHD Lawsuit

In our December 5th, 2023 Tylenol Autism Lawsuit update, Attorney Sean T. Keith discusses the upcoming Daubert hearing scheduled for December 7th, which is crucial for presenting scientific evidence linking acetaminophen use to autism and ADHD.

This hearing is significant as it will determine whether our scientific theories are solid enough to proceed with the case.

We also touch upon the recent developments involving Rite Aid’s bankruptcy and its impact on the lawsuit.

Our focus is on ensuring that all evidence presented adheres to scientific norms, as this will be key in moving forward with the trials and eventual resolution of the case.

To save you some time, here are the key points discussed in our December 5th, 2023 update on the Tylenol (acetaminophen) Autism and ADHD litigation:

• Upcoming Daubert hearing on December 7th to present scientific evidence linking acetaminophen to autism and ADHD.
• Importance of the Daubert hearing in determining the validity of our scientific theories.
• Recent development of Rite Aid’s bankruptcy and its implications for the lawsuit.
• Emphasis on adhering to scientific norms in presenting evidence for the case.

In our October 27th, 2023 Tylenol Autism Lawsuit update, Attorney Sean T. Keith discusses the ongoing process of the Daubert motion, which seeks to determine the admissibility of expert testimony in court.

This motion is crucial as it acts as a gatekeeper to the scientific evidence we present, ensuring it meets specific standards.

The outcome of this motion will be a significant indicator of the success of the plaintiffs’ claims.

We anticipate significant news for plaintiffs involved in the Tylenol Autism and ADHD Lawsuit by December or January of 2023.

To save you some time, here are the key points discussed in our October 27th, 2023 update on the Tylenol (acetaminophen) Autism and ADHD litigation:

• The ongoing Daubert motion and its importance in the litigation process.
• The judge’s role as a gatekeeper to the scientific evidence presented.
• Our positive outlook on overcoming this hurdle in the litigation.
• Anticipation of a significant update by December or January.

We recently met with the defendants to discuss and finalize the plaintiff’s fact sheet.

This sheet will be crucial as it will contain information we’ve gathered from our clients, which will be used to create individual fact sheets for each client.

The next significant step in this lawsuit is the Daubert hearing, which will delve into the science behind our claims.

This phase is pivotal as it will determine the validity of our scientific arguments.

The outcome of this hearing will be a strong indicator of the success of our claims.

To save you some time, here are the key points discussed in our video covering the October 4th, 2023 Tylenol Autism & ADHD Lawsuit Update:

• Finalization of the plaintiff’s fact sheet.
• Introduction to the Daubert hearing, which will assess the scientific basis of our claims.
• The importance of the Daubert hearing in determining the future of the lawsuit.
• The potential impact of the FDA’s recent letter on our case.

In our September 11th, 2023 Tylenol Autism Lawsuit update, Attorney Sean T. Keith discusses the FDA’s decision not to submit an opinion on the labeling of Tylenol.

Despite the FDA’s previous extension to submit an opinion, they have chosen to avoid direct involvement in the acetaminophen lawsuits.

While defendants reference a March 2023 FDA study to support their claims, our attorney Sean Keith highlights the limited data availability from the FDA and emphasizes that expert research challenges the FDA’s findings.

If you or a loved one experienced birth injuries due to Tylenol use during pregnancy, we encourage you to explore potential compensation options.

To save you some time, here are the key points discussed in our video covering the Tylenol Autism & ADHD Lawsuit Update:

• The FDA decided not to submit an opinion on Tylenol labeling.
• The FDA typically does not get involved in private litigations.
• A March 2023 FDA study is cited by defendants, but its findings are challenged by expert research.
• Our focus is on the inadequate warning label, emphasizing that the risks have been known for a long time.

In our August 21st, 2023 Tylenol Autism & ADHD Lawsuit update, Attorney Sean T. Keith discusses the recent decision by the court to extend the FDA’s window to respond and provide their opinion on the product warning label for Tylenol.

This response from the FDA could have significant implications on preemption claims, which would directly influence the ongoing lawsuit.

The court has now given the FDA until mid-September 2023 to share their response.

To save you some time, here are the key points discussed in our August 21st update video covering the Tylenol Autism & ADHD Lawsuit:

• Sean explains the court’s decision to extend the FDA’s response window.
• He further elaborates on the potential impact of the FDA’s response on preemption claims.
• Sean then discusses three (3) possible responses the FDA could provide.
• Sean emphasizes the significance of the warning label and its relation to the lawsuit.
• Lastly, Sean shares his anticipation of the FDA’s decision by September 15th, 2023.

In our August 18th, 2023 Tylenol Autism & ADHD Lawsuit update, Attorney Sean T. Keith provides an update on the ongoing acetaminophen autism and ADHD litigation taking place in federal court in Manhattan.

Sean dives into the general causation phase of the litigation, where plaintiffs aim to establish proof for the court that there is a cause and effect relationship between the intake of acetaminophen by pregnant women and the onset of autism and ADHD in their children after birth.

This phase involves both sides presenting their expert reports and taking depositions.

The outcome of this phase will determine if our scientific evidence stands up to scrutiny.

To save you some time, here are the key points discussed in our video covering the Tylenol Autism & ADHD Lawsuit:

• Sean discusses the general causation phase and its significance.
• Sean presents expert reports and explains the process of taking depositions.
• Sean mentions the challenges faced and the studies being argued upon by both sides.

In this June 2023 Tylenol Autism ADHD Lawsuit Update video, Attorney Sean T. Keith provides an update on the ongoing Acetaminophen MDL (Multi-District Litigation) lawsuit.

Sean discusses two (2) significant court orders that have been issued since the last update:

1. One affecting cases in Texas and California
2. The other related to the administrative aspect of the lawsuit.

Sean also continues to emphasize the importance of completing all required forms and documents for the Tylenol lawsuit (Acetaminophen MDL).

To save you some time, here are the key points discussed in our June 2023 Tylenol Lawsuit Update video:

• The court has issued two (2) significant orders since our last update in May 2023.
• The first order could potentially affect cases in Texas due to the state’s “Safe Harbor Act“.
  • The Safe Harbor Act protects retailers that follow FDA guidelines from being sued.
  • However, this argument was not successful when tried in California.
• The second order is related to the Plaintiff Fact Sheet, a form that plaintiffs need to fill out within a certain period of time from filing a lawsuit.
  • It is crucial for plaintiffs to complete all forms, questionnaires, and other onboarding documents as quickly as possible.

If you or a loved one suffered birth injuries due to Tylenol use during pregnancy, you may qualify for compensation.

If you have any questions or if you’re getting requests for information from either Keith Law Group or Beasley Allen, it’s important to respond quickly.

The Tylenol Autism Lawsuit is ongoing and our lawyers are talking to clients about their potential cases. 

In recent developments, a Texas judge granted a motion to dismiss failure to warn claims against major retailers like CVS, Target, and Walmart, citing a state law that protects distributors if FDA-approved packaging is used.

This decision halts failure to warn lawsuits in Texas but leaves other claims in progress.

In California, a similar motion was denied, indicating the outcome may vary depending on the state.

If you used Tylenol during pregnancy and your child was diagnosed with ASD, ADHD, or other developmental disorders, consider contacting Keith Law Group for a free consultation regarding a potential Tylenol Lawsuit.

You can also use this chatbot on this page to find out if you qualify for a Tylenol Lawsuit instantly. 

In the following video Sean Keith provides another May 2023 update on the Tylenol acetaminophen litigation.

You can watch the video below for the complete update.

In brief, here are the key takeaways from the mid-May 2023 updates for the Tylenol Lawsuit:

• As previously discussed, studies indicate a potential link between prenatal exposure to acetaminophen and ASD/ADHD in children.
• A consensus statement by 91 experts calls for caution in using acetaminophen during pregnancy.
• The court issued an invitation to the FDA to determine if warning labels should be added to acetaminophen products regarding ASD/ADHD risks.
• The FDA has until July 23rd to respond, and its response will impact the litigation.
• The court’s decision on preemption and label changes will depend on the FDA’s response.

In the following video Sean Keith provides a May update on the Tylenol acetaminophen litigation.

You can watch the video below for the complete update.

To save you some time, here are the key takeaways from the May updates for the Tylenol Lawsuit:

• Judge Coat entered three (3) opinions, one of which addressed the science behind the failure to warn claims.
• Preemption is a hurdle in prescription drug and product liability cases.
• Manufacturers and retailers cannot use lack of FDA approval to justify not changing the label.
• Preemption does not prevent plaintiffs from bringing lawsuits.
• Last week, the court ruled twice that preemption does not affect the plaintiffs’ case.

In the following video Sean Keith provides an April update on the Tylenol acetaminophen litigation.

In summary, the litigation is very busy right now as documents are being exchanged and reviewed from the manufacturers of acetaminophen.

As a reminder, this case is a failure to warn case, alleging that manufacturers and retailers knew about the possible dangers of acetaminophen taken during pregnancy and failed to warn of that.

The manufacturers and retailers should have simply added one sentence to warn of the possible dangers for pregnant women.

The court approved a plaintiff profile form about 10 days ago. When cases get filed, plaintiffs will need to help fill out the plaintiff profile form, which will include using medical records to complete the form.

Litigation is ongoing and a ton of important work is being done, so we will release another update by the end of this month!

The Tylenol MDL is growing. Cases are being added by the dozens each month, and more developments are being made in the logistical approach to the litigation.

Just last month, a Special Master was appointed to gather claimant information.

Visit this page for more updates on the Tylenol Lawsuit as they become available.

Contact Keith Law Group for a free consultation, or use the chatbot on this page to see if you qualify for a Tylenol Autism ADHD Lawsuit instantly.

199+ Tylenol cases have now been filed on behalf of children who suffer from autism and ADHD as a result of their mother’s Tylenol use during pregnancy.

As cases continue to be filed the Tylenol injury lawyers at Keith Law Group continue to accept new clients.

If you or a loved one suffered birth injuries due to Tylenol use during pregnancy, you may qualify for compensation.

This week an incredibly important decision was made by Senior U.S. District Judge Denise Cote in the Southern District of New York.

You can listen to the details of the update by watching the video below, which details the latest update in the Tylenol Autism ADHD Lawsuit:

Acetaminophen Autism-ADHD Lawsuits are being consolidated in multidistrict litigation (MDL) in the US District Court: Southern District of New York.

The Judicial Panel on Multidistrict Litigation (JPML) certified the creation of an MDL that names the manufacturers of generic acetaminophen as defendants, including Walmart, Walgreens, CVS, and other companies.

MDL is a legal procedure used in cases where injuries and causation are similar across several lawsuits, centralizing them in a single US District Court to make them easier to manage and ensure that there is a standard held across all similar cases in terms of court rulings.